Premium
Delayed hypersensitivity in patients treated by curative radiotherapy Its relation to tumor response and short‐term survival
Author(s) -
Bosworth J. L.,
Ghossein N. A.,
Brooks T. L.
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197508)36:2<353::aid-cncr2820360209>3.0.co;2-u
Subject(s) - medicine , delayed hypersensitivity , complete response , radiation therapy , surgery , gastroenterology , immunology , chemotherapy , antigen
Delayed hypersensitivity, as determined by skin reactivity to 2‐4 dinitrochlorobenzene (DNCB), was tested in 112 patients prior to their undergoing curative radiotherapy. Of the strong DNCB reactors, 84% had an excellent radiation tumor response, while only 48% of the negative reactors had an equivalent response. Almost twice as many strong DNCB reactors were alive and free of disease (NED) at 6 months (70% vs. 38% for nonreactors). Similarly, the positive DNCB reactors had a median survival of 18 months, compared to 10 months for the nonreactors.